| Abstract |
Several known water soluble [Cu(1 kappa N,O-2:2 kappa O-HL1)(S)](2) [S = CH3OH (1), (CH3)(2)NCHO (2)] and [Cu(kappa N-HL1)(en)(2)]center dot CH3OH center dot H2O (3) Cu-II complexes were prepared by reaction of Cu-II nitrate hydrate with the new (E/Z)-4-(2-(1-cyano-2-ethoxy-2-oxoethylidene)hydrazinyl)-3-hydroxybenzoi c acid (H3L1), in the presence (for 3) or absence (for 1 and 2) of ethylenediamine (en), while the Fe-III complex [Fe(kappa N-3-HL2)(2)] (4) was synthesized by treatment of iron(III) chloride hexahydrate with the new (1E,1E)-N ,2-di(1H-1,2,4-triazol-3-yl)diazenecarbohydrazonoyl cyanide (H3L2). The interaction of calf thymus DNA (CT DNA) and bovine serum albumin (BSA protein) with complexes 1-4 has been investigated by absorption and fluorescence titration methods. The observed DNA binding constants, number of DNA binding sites (s <= 1) for the complexes and viscosity data suggest the intercalative mode of binding to CT DNA. All the complexes show good binding propensity to the BSA protein, giving K-BSA values of 0.97(+/- 0.10) x 10(6) (1), 1.19(+/- 0.09) x 10(6) (2), 0.50(+/- 0.01) x 10(6) (3) and 1.06(+/- 0.08) x 10(6) M-1 (4). An in vitro anti-proliferative study establishes the anticancer potency of complexes 1-4 and cisplatin against the human cervical (HeLa) and breast (MCF7) cancer cell lines; noncancer breast epithelial (MCF10) cells were also investigated. The observed IC50 values of complexes 1 (8.3, 11.9 and 44.8 mu M), 2 (7.0, 7.1 and 35.6 mu M), 3 (18.1, 20.4 and 58.8 mu M), 4 (13.2, 15.1 and 79.4 mu M) and cisplatin (4.02, 3.42 and 89.5 mu M) against the HeLa, MCF7 and MCF-10a cells, respectively, suggest that 2 can be explored further as a potential anticancer drug. |
